Xeris Biopharma Holdings (XERS) Financial Statements & Analysis

Xeris Biopharma Holdings (XERS) Income Statement

Xeris Biopharma Holdings reported revenue of $291.85M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 43.7% from $203.07M a year earlier. Net income was $554.00K, a net margin of 0.2%. Gross margin was 85.4% and operating margin 8.5%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $92.10M, up 28.7% from the same quarter a year earlier.

Xeris Biopharma Holdings Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Xeris Biopharma Holdings, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	291.85	203.07	163.91	110.25	49.59	20.44	2.72	2.47	1.56
Cost of Revenue	42.57	36.83	28.65	22.63	13.32	9.33	1.60	0.04	0.00
Gross Profit	249.28	166.24	135.27	87.61	36.27	11.11	1.12	2.42	1.55
Operating Expenses
Research & Development	31.17	25.56	22.34	20.97	25.16	20.92	60.44	40.65	20.17
Selling, General & Administrative	182.37	163.48	146.10	137.75	116.06	73.73	63.06	21.11	8.02
Operating Expenses	224.38	199.88	179.28	169.55	151.43	94.65	123.50	61.77	28.18
Operating Income	24.90	-33.65	-44.01	-81.94	-115.16	-83.55	-122.38	-59.34	-26.63
Other Income/Expense
Interest Income	4.74	5.32	4.75	2.58	0.31	4.47	2.81	1.61	0.12
Interest Expense	29.08	-30.49	26.61	-14.10	-7.18	7.36	7.16	2.55	0.00
Other Income/Expense	-24.34	-23.46	2.36	-14.14	-7.57	-7.70	-3.66	-0.74	0.08
Income
Income Before Tax	0.55	-57.10	-63.50	-96.08	-122.73	-91.25	-126.04	-60.08	-26.55
Income Tax Expense	0.00	-2.27	-1.25	-1.42	0.00	-0.11	-0.46	0.00	0.00
Net Income	0.55	-54.84	-62.26	-94.66	-122.73	-91.14	-125.58	-60.08	-26.55
Net Income - Continuous Operations	0.55	-54.84	-62.26	-94.66	-122.73	-91.14	-125.58	-60.08	-26.55
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	42.33	-21.58	-23.74	-69.70	-103.62	-79.12	-117.80	-57.22	-26.38
EBIT	29.64	-33.65	-36.90	-81.94	-105.50	-81.55	-	-	-
Depreciation & Amortization	10.84	12.07	10.84	12.24	1.88	1.47	1.08	0.32	0.18
Earnings Per Share
Basic EPS	-	-	-	-1.00	-2.00	-2.00	-3.00	-5.00	-13.00
Diluted EPS	-	-	-	-1.00	-2.00	-2.00	-3.00	-5.00	-13.00
Basic Shares Outstanding	160.43	146.77	137.67	135.63	79.03	42.64	26.11	12.05	2.03
Diluted Shares Outstanding	172.74	146.77	137.67	135.63	79.03	42.64	26.11	12.05	2.03

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Xeris Biopharma Holdings Financial Statements

What was Xeris Biopharma Holdings's revenue in fiscal 2025?

Xeris Biopharma Holdings reported revenue of $291.85M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 43.7% from $203.07M a year earlier.

Is Xeris Biopharma Holdings profitable?

Yes. Xeris Biopharma Holdings earned net income of $554.00K in fiscal 2025, a net margin of 0.2%. In fiscal 2024 it lost $54.84M.

What is Xeris Biopharma Holdings's operating margin?

Xeris Biopharma Holdings's operating income was $24.90M on revenue of $291.85M in fiscal 2025, an operating margin of 8.5%, compared with -16.6% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition